Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 8/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 8/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 5/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 5/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740566 | 0.87 | PIM1 (0.48) | KCNQ3KCNQ2PIM1FFAR1KMT2A | |
| SCHEMBL3730695 | 0.84 | GPR84 (0.47) | PIM1FFAR1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL3743226 | 0.83 | PIM1 (0.42) | KCNQ3KCNQ2PIM1FFAR1MMP13 | |
| SCHEMBL3746155 | 0.82 | PIM1 (0.43) | KCNQ3KCNQ2KCNE1KCNQ1PIM1 | |
| SCHEMBL3733539 | 0.80 | SLC5A1 (0.50) | PIM1FFAR1ALDH1A1MAPTRAB9A | |
| SCHEMBL3730053 | 0.79 | PIM1 (0.47) | PIM1FFAR1RAB9AKMT2AMMP13 | |
| SCHEMBL3738007 | 0.75 | PDPK1 (0.44) | PIM1FFAR1 | |
| SCHEMBL3739732 | 0.75 | PIM1 (0.43) | PIM1ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL3738096 | 0.75 | PDE4D (0.65) | KCNQ3KCNQ2FFAR1MAPTRAB9A | |
| SCHEMBL3740298 | 0.75 | PPARD (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | KCNQ3 1664/4885KCNQ2 2251/4885KCNE1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.